Valuation: Haleon plc

Capitalization 33.88B 43.18B 41.1B 38.09B 61.16B 3,665B 67.77B 474B 175B 1,505B 162B 159B 6,566B P/E ratio 2024 *
22.6x
P/E ratio 2025 * 20.1x
Enterprise value 41.71B 53.17B 50.61B 46.9B 75.3B 4,512B 83.45B 584B 216B 1,853B 200B 195B 8,085B EV / Sales 2024 *
3.72x
EV / Sales 2025 * 3.57x
Free-Float
-
Yield 2024 *
1.66%
Yield 2025 * 1.9%
More valuation ratios * Estimated data
Dynamic Chart
1 day+0.27%
1 week-0.77%
Current month-0.03%
1 month+3.00%
3 months-4.78%
6 months+13.29%
Current year+16.34%
More quotes
1 week
367.50
Extreme 367.5
378.90
1 month
352.70
Extreme 352.7
382.80
Current year
308.37
Extreme 308.3696
400.65
1 year
308.37
Extreme 308.3696
400.65
3 years
241.17
Extreme 241.1735
400.65
5 years
241.17
Extreme 241.1735
400.65
10 years
241.17
Extreme 241.1735
400.65
More quotes
Director TitleAgeSince
Chief Executive Officer 57 2021-07-21
Director of Finance/CFO 55 2024-10-31
Chief Tech/Sci/R&D Officer - 2021-12-15
Manager TitleAgeSince
Director/Board Member 57 2022-05-22
Director/Board Member 69 2022-07-17
Director/Board Member 57 2022-07-17
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi. ($)
+0.27%-0.77%+15.21% - 43.21B
-0.50%-0.03%+33.70%+229.18%724B
+0.03%+0.86%+17.04%+108.44%491B
-0.25%-3.60%-3.36%-10.05%360B
-0.51%-3.36%+17.68%+41.50%312B
-2.69%+0.39%-2.65%+38.62%263B
-1.32%-0.94%+0.20%-32.16%236B
-1.78%-0.40%+3.85%+25.71%212B
-0.69%-4.70%+4.77%+18.92%204B
-0.68%-0.85%+2.46%+29.72%149B
Average -0.58%-0.87%+8.89%+49.99% 299.34B
Weighted average by Cap. -0.48%-0.52%+13.10%+82.95%
See all sector performances

Financials

2024 *2025 *
Net sales 11.22B 14.31B 13.62B 12.62B 20.26B 1,214B 22.46B 157B 58.01B 499B 53.72B 52.56B 2,176B 11.47B 14.62B 13.91B 12.89B 20.7B 1,241B 22.94B 161B 59.27B 509B 54.88B 53.7B 2,223B
Net income 1.49B 1.89B 1.8B 1.67B 2.68B 161B 2.97B 20.81B 7.68B 66.03B 7.11B 6.96B 288B 1.66B 2.12B 2.02B 1.87B 3B 180B 3.33B 23.3B 8.6B 73.91B 7.96B 7.79B 323B
Net Debt 7.83B 9.99B 9.51B 8.81B 14.14B 847B 15.67B 110B 40.49B 348B 37.49B 36.68B 1,519B 7.02B 8.95B 8.52B 7.89B 12.67B 759B 14.04B 98.27B 36.28B 312B 33.59B 32.87B 1,361B
More financial data * Estimated data
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Employees
25,408
Calendar
More about the company
Date Price Change Volume
24-12-10 374.20 p +0.27% 17,515,220
24-12-09 373.20 p -0.48% 12,438,370
24-12-06 375.00 p -0.24% 22,199,300
24-12-05 375.90 p -0.48% 15,341,170
24-12-04 377.70 p +0.08% 16,945,080

Delayed Quote London S.E., December 10, 2024 at 11:35 am EST

More quotes
Trading Rating
Investor Rating
ESG Refinitiv
B
surperformance-ratings-light-chart HALEON-PLCMore Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.742GBP
Average target price
3.950GBP
Spread / Average Target
+5.56%
Consensus

Quarterly revenue - Rate of surprise